Immunolocalization of neurokinin 1 receptor in WHO grade 4 astrocytomas, oral squamous
cell and urothelial carcinoma

Riffat Mehboob; Maher Kurdi; Saleh Baeesa; Taher Fawzy Halawa; Imrana Tanvir; Yazid Maghrabi; Sahar Hakamy; Rothaina Saeedi; Rana Moshref; Hisham Nasief; Amber Hassan; Humaira Waseem; Shahida Rasool; Basem Bahakeem; Eyad Faizo; Yousef Katib; Ahmed Bamaga; Nashwa Aldardeir

doi:10.5114/fn.2022.116469

eISSN: 1509-572x
ISSN: 1641-4640

Folia Neuropathologica

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2022
vol. 60

Send email

Copy url:

abstract:

Original paper

Immunolocalization of neurokinin 1 receptor in WHO grade 4 astrocytomas, oral squamous cell and urothelial carcinoma

Riffat Mehboob

¹

,

Maher Kurdi

²

,

Saleh Baeesa

³

,

Taher Fawzy Halawa

⁴

,

Imrana Tanvir

²

,

Yazid Maghrabi

⁵

,

Sahar Hakamy

⁶

,

Rothaina Saeedi

³

,

Rana Moshref

⁷

,

Hisham Nasief

⁸

,

Amber Hassan

⁹

,

Humaira Waseem

¹⁰

,

Shahida Rasool

¹

,

Basem Bahakeem

¹¹

,

Eyad Faizo

¹²

,

Yousef Katib

¹³

,

Ahmed K. Bamaga

^{14, 15}

,

Nashwa Aldardeir

¹⁶

Lahore Medical Research Center, LLP, Lahore, Pakistan

Department of Pathology, Faculty of Medicine in Rabigh, King Abdulaziz University, Saudi Arabia

Division of Neurosurgery, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia

Department of Pediatrics, Rabigh Faculty of Medicine, King Abdulaziz University, Saudi Arabia

Neurosciences Department, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia

Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia

Section of Neurosurgery, King Abdulaziz Medical City, Jeddah, Saudi Arabia

Department of Obstetrics and Gynaecology, Faculty of Medicine, Jeddah, Saudi Arabia

University of Milan, Milan, Italy

10.

Fatima Jinnah Medical University, Lahore, Pakistan

11.

Faculty of Medicine, Umm-Alqura University, Makkah, Saudi Arabia

12.

Division of Neurosurgery, Department of Surgery, Faculty of Medicine, Tabuk University, Tabuk, Saudi Arabia

13.

Department of Radiology, Faculty of Medicine, Taibah University, Al Madinah Al Munawwarah, Saudi Arabia

14.

Neurology Division, Paediatric Department, Faculty of Medicine, King Abdulaziz University Hospital, King Abdulaziz University, Jeddah, Saudi Arabia

15.

Paediatric Department, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia

16.

Department of Obstetrics and Gynaecology, Faculty of Medicine, King Abdulaziz University, Saudi Arabia

Folia Neuropathol 2022; 60 (2): 165-176

DOI: https://doi.org/10.5114/fn.2022.116469

Online publish date: 2022/06/30

View full text Get citation

PlumX metrics:

Introduction
Neurokinin-1 receptor (NK-1R) induces inflammatory reactions in peripheral tissues but its regulatory effects in target tissues is dependent on receptor signalling. Substance P (SP) has a high affinity for the NK-1R, to which it binds preferentially. We aimed to investigate the expression of NK-1R in World Health Organization (WHO) grade 4 astrocytomas as well as in oral squamous cell carcinoma (OSCC) and urothelial carcinoma, and its association with disease progression.

Material and methods
The study included tissue samples from 19 brain astrocytomas, 40 OSCCs and 10 urothelial carcinomas. NK-1R expression was quantitatively assessed in the tumour cells using immunohistochemistry. The relationship between NK-1R expression in astrocytomas and recurrence-free interval has been explored.

Results
The results showed that the NK-1R was intensely expressed in patients with WHO grade 4 astrocytoma, OSCC and urothelial carcinoma. However, cases clinically diagnosed as a low-grade cancer showed reduced NK-1R expression.

Conclusions
NK-1R is overexpressed in all cases of WHO grade 4 astrocytoma, OSCC and urothelial carcinoma. The ubiquitous presence of SP/NK-1R complex during tumour development and progression suggests a possible therapeutic key strategy to use NK-1R antagonist as an adjuvant therapy in the future.

keywords:

Immunolocalization of neurokinin 1 receptor in WHO grade 4 astrocytomas, oral squamous cell and urothelial carcinoma

neurokinin-1 receptor, immunohistochemistry, substance P, immunolocalization, glioblastoma, oral squamous cell carcinoma, urothelial carcinoma